Azeria Banks £32m For New Breast Cancer Approach
UK Firm Added To Syncona Portfolio
Azeria has closed a significant series B round to fund development of novel breast cancer drugs targeting pioneer factors.
You may also be interested in...
The Italian firm has some talking to do with the US FDA before it can unblind Phase III data on sarizotan, its Rett syndrome therapy which could be "potentially transformative" for Newron.
The French drugmaker is paying $2.5bn to get hold of THOR-707 which it claims has the potential to become the best-in-class IL-2 therapeutic for solid tumors, thanks to improved pharmacology and less frequent dosing.
The Swiss giant is hoping to get seven more approvals for its blockbuster immunology drug over the next 10 years.